About this trial
Environmental pollutants have emerged as a major global health concern, with growing evidence linking exposure to both traditional contaminants such as heavy metals (lead, mercury, cadmium, arsenic) and novel pollutants-including micro- and nanoplastics, per- and polyfluoroalkyl substances (PFAS), antibiotics, and endocrine-disrupting chemicals-to adverse neurological outcomes. These pollutants can cross or disrupt the blood-brain barrier, accumulate in neural tissue, and trigger oxidative stress, inflammation, epigenetic modifications, and metabolic reprogramming.
Brain tumours and cerebrovascular diseases represent two major categories of neurosurgical disorders with high morbidity and mortality. However, their interaction with environmental pollutant exposure remains poorly understood. Recent studies suggest that pollutant-induced molecular alterations, such as aberrant DNA methylation, lipid metabolism disruption, and neurovascular endothelial dysfunction, may contribute to tumour initiation, malignant progression, aneurysm formation, and stroke occurrence.
Given the increasing human exposure to these pollutants and the lack of large-scale clinical data, it is urgent to establish a systematic investigation in neurosurgical patients. This study aims to profile pollutant exposure (heavy metals, PFAS, microplastics, and other novel contaminants) using multi-biospecimen analysis (blood, urine, hair, tumour and peri-tumour tissues), and to explore their mechanistic links to the pathogenesis of brain tumours and cerebrovascular diseases. The findings are expected to provide new evidence for understanding environment-brain interactions and to identify potential biomarkers for disease risk stratification and prevention.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
18 years of age or older;
Able to give informed consent to participate in the research.
Disqualifiers
Refusal to participate.
Pregnant or breastfeeding woman.
Trial population
Patients with brain tumours or cerebrovascular diseases who need surgical resection.
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Overall Survival (OS)
OS is defined as the time from the sample collection date to death due to any cause. All other participants will be censored at the last date known to be alive.
Secondary outcomes
Progression-Free Survival (PFS)
PFS is defined as the duration of time from sample collection date to time of progression or death, whichever occurs first.
modified Rankin Scale (mRS)
Patients' mRS scores at 90 days after sample collection.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Beijing Tiantan Hospital
Lead sponsor
Chinese Research Academy of Environmental Sciences
Collaborator
Nanjing University
Collaborator
Nanjing Institute of Environmental Sciences
Collaborator
Chinese Academy of Environmental Planning
Collaborator
Peking Union Medical College
Collaborator
National Human Brain Bank for Development and Function
Collaborator